D3L-002

N/A

Report date: 2024/11/12 15:24:16

Base Information

Drug NameD3L-002
Drug Alias NameD3L-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTransmembrane protein PVRIG inhibitorsT cell immunoglobulin and ITIM domains inhibitors
TargetsTransmembrane protein PVRIGT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesD3 Bio (Wuxi) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesD3 Bio (Wuxi) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A